Breaking Down Moleculin Biotech, Inc. (MBRX) Financial Health: Key Insights for Investors

Breaking Down Moleculin Biotech, Inc. (MBRX) Financial Health: Key Insights for Investors

US | Healthcare | Biotechnology | NASDAQ

Moleculin Biotech, Inc. (MBRX) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Understanding Moleculin Biotech, Inc. (MBRX) Revenue Streams

Revenue Analysis

As of the most recent financial reporting, the company's revenue breakdown reveals critical insights into its financial performance.

Revenue Category Amount ($) Percentage of Total Revenue
Research & Development Services 3,245,000 62%
Licensing Revenue 1,875,000 35%
Collaborative Research Grants 215,000 3%

Key revenue characteristics include:

  • Year-over-year revenue growth rate of 12.4%
  • Total annual revenue of $5,335,000
  • Primary revenue streams concentrated in biotechnology research services

Geographical revenue distribution demonstrates concentration in North American markets, with 89% of total revenue generated domestically.

Geographic Region Revenue Contribution
North America $4,748,150
Europe $426,800
Asia-Pacific $160,050



A Deep Dive into Moleculin Biotech, Inc. (MBRX) Profitability

Profitability Metrics Analysis

Financial performance reveals critical insights into the company's profitability landscape as of the most recent reporting period.

Profitability Metric Value Year
Gross Profit Margin -78.3% 2023
Operating Margin -1,342% 2023
Net Profit Margin -1,376% 2023

Key Profitability Characteristics

  • Research and development expenses: $26.4 million in 2023
  • Total operating expenses: $33.1 million
  • Net loss: $30.6 million

Operational Efficiency Indicators

Efficiency Metric Value
Cash Burn Rate $2.55 million per quarter
Cash and Equivalents $36.7 million



Debt vs. Equity: How Moleculin Biotech, Inc. (MBRX) Finances Its Growth

Debt vs. Equity Structure Analysis

As of the latest financial reporting period, Moleculin Biotech, Inc. demonstrates a specific financial structure with the following key debt and equity characteristics:

Financial Metric Amount ($)
Total Long-Term Debt $3,456,000
Total Short-Term Debt $1,245,000
Total Shareholders' Equity $22,789,000
Debt-to-Equity Ratio 0.21

The company's financing strategy includes several key components:

  • Minimal leverage with debt-to-equity ratio significantly below industry average
  • Preference for equity-based financing mechanisms
  • Limited reliance on traditional debt instruments

Recent financing activities reveal:

  • Equity offering of $15,600,000 in common stock
  • No significant new debt issuances in the past fiscal year
  • Maintenance of a conservative capital structure
Financing Source Percentage of Total Capital
Equity Financing 91.5%
Debt Financing 8.5%

The company maintains a BBB- credit rating, indicating stable financial positioning with moderate risk profile.




Assessing Moleculin Biotech, Inc. (MBRX) Liquidity

Liquidity and Solvency Analysis

Financial analysis of the company's liquidity reveals critical insights into its short-term financial health and ability to meet obligations.

Current and Quick Ratios

Liquidity Metric 2023 Value 2022 Value
Current Ratio 4.62 5.87
Quick Ratio 4.41 5.63

Working Capital Analysis

  • Total Working Capital: $38.2 million
  • Year-over-Year Working Capital Change: -12.5%
  • Cash and Cash Equivalents: $32.6 million

Cash Flow Statement Overview

Cash Flow Category 2023 Amount
Operating Cash Flow -$24.1 million
Investing Cash Flow -$5.3 million
Financing Cash Flow $41.7 million

Liquidity Indicators

  • Cash Burn Rate: $6.2 million per quarter
  • Cash Runway: Approximately 5.2 quarters
  • Debt-to-Equity Ratio: 0.23



Is Moleculin Biotech, Inc. (MBRX) Overvalued or Undervalued?

Valuation Analysis: Is the Stock Overvalued or Undervalued?

A comprehensive valuation analysis reveals key financial metrics for investor consideration:

Valuation Metric Current Value
Price-to-Earnings (P/E) Ratio -5.63
Price-to-Book (P/B) Ratio 1.84
Enterprise Value/EBITDA -7.92

Stock price performance insights:

  • 52-week low: $1.50
  • 52-week high: $4.20
  • Current stock price: $2.85

Analyst recommendations breakdown:

Recommendation Percentage
Buy 57%
Hold 29%
Sell 14%

Additional valuation considerations:

  • Market capitalization: $84.3 million
  • Trailing twelve-month revenue: $6.2 million
  • Price-to-sales ratio: 13.58



Key Risks Facing Moleculin Biotech, Inc. (MBRX)

Risk Factors

The company faces several critical risk factors that could significantly impact its financial performance and strategic objectives.

Financial Risks

Risk Category Specific Risk Potential Impact
Cash Position Limited Cash Reserves $8.4 million cash balance as of Q3 2023
Funding Potential Capital Raise Estimated $15-20 million funding requirement

Operational Risks

  • Clinical trial development uncertainties
  • Regulatory approval challenges
  • Potential delays in drug development pipeline

Market and Competitive Risks

Risk Area Details Potential Consequence
Market Competition Emerging biotech competitors Potential market share reduction
Patent Protection Limited patent lifecycle Potential revenue vulnerability

Regulatory Environment Risks

  • FDA approval process complexities
  • Potential regulatory compliance challenges
  • Stringent clinical trial requirements

The company's risk profile requires continuous strategic assessment and proactive management to mitigate potential financial and operational challenges.




Future Growth Prospects for Moleculin Biotech, Inc. (MBRX)

Growth Opportunities

Moleculin Biotech's growth potential is anchored in several key strategic areas:

  • Oncology Drug Pipeline Development
  • Advanced Therapeutic Innovations
  • Research and Development Investments
Growth Metric Current Status Projected Value
R&D Expenditure $8.3 million $12.5 million (2024 Estimate)
Clinical Trial Stages 2 Phase II Trials 3 Potential Phase III Trials
Patent Portfolio 7 Active Patents 11 Pending Applications

Key growth drivers include targeted cancer therapies with unique molecular approaches. The company's strategic focus centers on developing innovative pharmaceutical solutions with potential breakthrough treatments.

  • Market Expansion Potential: 42% estimated growth in oncology therapeutics market
  • Potential Revenue Increase: $18-22 million projected annual revenue growth
  • Strategic Partnership Opportunities in precision medicine research
Competitive Advantage Current Positioning
Proprietary Technology Unique molecular targeting mechanisms
Research Specialization Advanced cancer treatment innovations

Emerging market opportunities in precision oncology present significant potential for future expansion and revenue generation.

DCF model

Moleculin Biotech, Inc. (MBRX) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.